We invest in life science companies whose key source of value creation is innovation and growth. Our investment comes with an engaged and supportive approach to help a company, its board and its management realize their full potential.
What we do
Our investment approach
The Principal Investment team targets investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers.
We provide access to evergreen funds across the entire capital structure. Our investments may be permanent, making Novo Holdings a true long-term partner.
In addition to capital and engagement, an investment from Novo Holdings also provides access to our extensive network within the life science industry. We use our experience and expertise from our ownership of world-leading life science companies to actively support a board and management in realizing their strategic ambitions.
At the end of 2017, the Principal Investments portfolio comprised twelve companies, with a total value of EUR 6.8 billion.
Meet our team
Our team consists of highly skilled professionals with a diverse set of backgrounds including industry, consulting, banking and private equity. We use our broad life science expertise to target long-term investment opportunities.
€ 4.2 bn
Value of investments at the end of 2016.
€ 870 M
Investments during 2016.
Novo Holdings acquires a 25% equity stake in Envirotainer.
Novo increases stake in SYNLAB
Novo A/S announces the proposed acquisition of a 19.95% shareholding in ConvaTec Group Plc
Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the US
Inogen Announces Fourth Quarter and Full Year 2016 Financial Results and Updates 2017Mar 01, 2017
BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
The Principal Investments team is based at our headquarters in Copenhagen, Denmark.
Novo Holdings A/S
Tuborg Havnevej 19
+45 3527 6500